Portnoy Law Firm and Pomerantz LLP said they are investigating possible securities fraud after Omeros disclosed a negative CHMP opinion on its narsoplimab application for TA-TMA in Europe.
Portnoy Law Firm and Pomerantz LLP said they are investigating potential claims on behalf of Omeros Corporation investors following the company's June 26, 2026 disclosure that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, adopted a negative opinion on the marketing authorization application for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Omeros said the decision followed an oral explanation meeting at which the company and four international experts presented their position. After the disclosure, Omeros shares fell $2.05, or 19.12%, to close at $8.67 on June 26, 2026. The firms said they are examining whether Omeros and certain officers or directors may have engaged in securities fraud or other unlawful business practices, and each invited investors to make contact regarding possible claims or class-action participation.